Zydus Lifesciences Q1 Results: Profit more than doubles on US sales growth
Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.
Zydus Lifesciences gets USFDA nod for generic rheumatoid arthritis treatment drug
Zydus Lifesciences has gained the US Food and Drug Administration's (FDA) approval to produce and market its Indomethacin suppositories. The drug is used to treat moderate to severe rheumatoid arthritis and acute flares of chronic disease, among other conditions. Zydus has been awarded 180-day CGT exclusivity to market the product after US authorities deemed there was a lack of competition.
HCL Tech, Nykaa and 8 other counters cross 20-day SMA
The stock market witnessed notable movements as several stocks surged above their 20-day Simple Moving Average (SMA) on 1st August 2023, indicating bullish momentum. Investors are closely observing these stocks for potential investment opportunities in the market
Stocks on the rise! DLF, Marico and more cross 50-day SMA
5 counters crossed their 50-day Simple Moving Average (SMA) on July 27, 2023. Marico and Zydus Wellness take the lead, alongside other prominent companies like Havells India and TCI Express, showcasing positive market momentum and growth potential
HUL, Shree Renuka Sugars among 10 stocks with RSI trending up
Relative Strength Index (RSI) is a valuable technical indicator which gives insights to make informed decisions. It tells about stock's momentum and potential price movements. RSI measures the speed and change of price movements on a scale from 0 to 100, and readings above 70 indicate an overbought condition, while readings below 30 suggest an oversold condition. Analysing RSI trends can help investors gauge a stock's potential for price reversals or continued momentum.
Confusing sugar wars: Defying West, India will go its own sweet way on aspartame
Reports say the World Health Organization is set to classify aspartame as a possible carcinogen. India's FSSAI, which initially banned a natural alternative sugar, stevia in 2011, reversed the order later and gave it its nod. It now says that India may not necessarily follow the West's path on aspartame, as India is currently in a 'powerful' situation.